Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.
作者信息
Borchert Robin J, Rittman Timothy, Passamonti Luca, Ye Zheng, Sami Saber, Jones Simon P, Nombela Cristina, Rodríguez Patricia Vázquez, Vatansever Deniz, Rae Charlotte L, Hughes Laura E, Robbins Trevor W, Rowe James B
出版信息
Neuropsychopharmacology. 2016 Jul;41(8):2188. doi: 10.1038/npp.2016.46.
Abstract
摘要
相似文献
1
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.
Neuropsychopharmacology. 2016 Jul;41(8):2188. doi: 10.1038/npp.2016.46.
2
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease.
Neuropsychopharmacology. 2016 Jul;41(8):2171-7. doi: 10.1038/npp.2016.18. Epub 2016 Feb 3.
3
Atomoxetine restores the response inhibition network in Parkinson's disease.
Brain. 2016 Aug;139(Pt 8):2235-48. doi: 10.1093/brain/aww138. Epub 2016 Jun 24.
4
Improving response inhibition in Parkinson's disease with atomoxetine.
Biol Psychiatry. 2015 Apr 15;77(8):740-8. doi: 10.1016/j.biopsych.2014.01.024. Epub 2014 Feb 7.
5
Atomoxetine and citalopram alter brain network organization in Parkinson's disease.
Brain Commun. 2019;1(1):fcz013. doi: 10.1093/braincomms/fcz013. Epub 2019 Sep 6.
6
The structural connectivity of discrete networks underlies impulsivity and gambling in Parkinson's disease.
Brain. 2019 Dec 1;142(12):3917-3935. doi: 10.1093/brain/awz327.
7
Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease.
Brain. 2021 Sep 4;144(8):2513-2526. doi: 10.1093/brain/awab142.
8
Abnormal intra- and inter-network functional connectivity of brain networks in early-onset Parkinson's disease and late-onset Parkinson's disease.
Front Aging Neurosci. 2023 Mar 24;15:1132723. doi: 10.3389/fnagi.2023.1132723. eCollection 2023.
9
Optimal subthalamic stimulation sites and related networks for freezing of gait in Parkinson's disease.
Brain Commun. 2023 Sep 4;5(5):fcad238. doi: 10.1093/braincomms/fcad238. eCollection 2023.
10
A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson's Disease.
Mov Disord Clin Pract. 2016 Nov 17;4(3):416-423. doi: 10.1002/mdc3.12455. eCollection 2017 May-Jun.
引用本文的文献
1
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.
Brain. 2022 Jun 30;145(6):1924-1938. doi: 10.1093/brain/awab452.
2
Mapping the effects of atomoxetine during response inhibition across cortical territories and the locus coeruleus.
Psychopharmacology (Berl). 2022 Feb;239(2):365-376. doi: 10.1007/s00213-021-05998-2. Epub 2021 Oct 25.
3
Neuromodulation of prefrontal cortex cognitive function in primates: the powerful roles of monoamines and acetylcholine.
Neuropsychopharmacology. 2022 Jan;47(1):309-328. doi: 10.1038/s41386-021-01100-8. Epub 2021 Jul 26.
4
Response inhibition in Parkinson's disease: a meta-analysis of dopaminergic medication and disease duration effects.
NPJ Parkinsons Dis. 2017 Jul 7;3:23. doi: 10.1038/s41531-017-0024-2. eCollection 2017.
5
Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z.
PLoS One. 2017 Apr 26;12(4):e0174774. doi: 10.1371/journal.pone.0174774. eCollection 2017.
6
The Psychoactive Designer Drug and Bath Salt Constituent MDPV Causes Widespread Disruption of Brain Functional Connectivity.
Neuropsychopharmacology. 2016 Aug;41(9):2352-65. doi: 10.1038/npp.2016.40. Epub 2016 Mar 21.
Zotero 插件